Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.64 -1.1%	$2.82	$0.80 ▼ $4.08	$966.50M	0.84	3.22 million shs	5.30 million shs
COGT Cogent Biosciences	$7.26 +0.4%	$5.53	$3.72 ▼ $12.61	$823.18M	1.82	1.30 million shs	1.43 million shs
FTLF FitLife Brands	$12.99 -2.5%	$14.29	$9.83 ▼ $17.75	$125.09M	0.81	16,864 shs	20,205 shs
TYRA Tyra Biosciences	$9.71 +5.2%	$9.79	$6.42 ▼ $29.60	$490.02M	1.07	281,520 shs	323,374 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-1.09%	+1.68%	+27.27%	+86.67%	+300.00%
COGT Cogent Biosciences	+0.41%	-3.07%	+50.62%	+5.22%	-17.41%
FTLF FitLife Brands	-2.48%	-2.04%	-10.91%	-2.70%	-25.77%
TYRA Tyra Biosciences	+5.20%	-4.99%	+4.52%	-5.82%	-43.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.0935 of 5 stars	3.6	2.0	4.0	3.5	0.8	0.6
COGT Cogent Biosciences	1.718 of 5 stars	3.4	3.0	0.0	1.2	0.0	0.6
FTLF FitLife Brands	3.7064 of 5 stars	3.7	3.0	0.0	1.9	3.3	1.9
TYRA Tyra Biosciences	2.1998 of 5 stars	3.5	1.0	0.0	2.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	85.44% Upside
COGT Cogent Biosciences	2.75	Moderate Buy	$14.57	100.71% Upside
FTLF FitLife Brands	3.33	Buy	$20.50	57.81% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	217.54% Upside

Current Analyst Ratings Breakdown

Latest FTLF, COGT, AKBA, and TYRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/29/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$21.00 ➝ $25.00
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/20/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
5/7/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/1/2025	AKBA Akebia Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
3/31/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.97	N/A	N/A	($0.23) per share	-15.83
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
FTLF FitLife Brands	$64.47M	1.89	$0.99 per share	13.15	$3.93 per share	3.31
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
FTLF FitLife Brands	$8.98M	$0.84	15.46	11.81	N/A	13.85%	25.59%	15.26%	N/A
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/6/2025 (Estimated)

Latest FTLF, COGT, AKBA, and TYRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A
3/27/2025	Q4 2024	FTLF FitLife Brands	$0.22	$0.21	-$0.01	N/A	N/A	N/A
3/27/2025	Q4 2024	TYRA Tyra Biosciences	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
COGT Cogent Biosciences	N/A	5.13	5.13
FTLF FitLife Brands	0.19	1.64	0.72
TYRA Tyra Biosciences	N/A	22.78	22.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
COGT Cogent Biosciences	N/A
FTLF FitLife Brands	2.32%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
COGT Cogent Biosciences	7.29%
FTLF FitLife Brands	61.30%
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable

FTLF, COGT, AKBA, and TYRA Headlines

Recent News About These Companies

Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 5.6% - Here's What Happened

June 23 at 4:15 PM | marketbeat.com

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of Stock

June 21 at 6:31 AM | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $93,575.04 in Stock

June 20, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in Stock

June 17, 2025 | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan Sells 6,814 Shares

June 16, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $154,650.00 in Stock

June 16, 2025 | marketbeat.com

Gilla Kaplan Sells 30,000 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

June 16, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 3% - What's Next?

June 16, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Up 7.1% - Time to Buy?

June 10, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Time to Buy?

June 9, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Buy" from Analysts

June 6, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading Down 6% - Here's What Happened

June 5, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short Interest

June 4, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stake Trimmed by Canaan Partners XI LLC

June 3, 2025 | marketbeat.com

Millennium Management LLC Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 31, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading 6.1% Higher - Here's Why

May 30, 2025 | marketbeat.com

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025 | prnewswire.com

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

May 9, 2025 | finance.yahoo.com

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025 | prnewswire.com

Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%

May 6, 2025 | aaii.com

Tyra Biosciences price target lowered to $28 from $29 at BofA

March 30, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF, COGT, AKBA, and TYRA Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.64 -0.04 (-1.09%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$3.64 0.00 (-0.11%)

As of 07:00 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Cogent Biosciences NASDAQ:COGT

$7.26 +0.03 (+0.41%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$7.34 +0.08 (+1.12%)

As of 06:08 AM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

FitLife Brands NASDAQ:FTLF

$12.92 -0.41 (-3.04%)

As of 06/23/2025 04:00 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Tyra Biosciences NASDAQ:TYRA

$9.71 +0.48 (+5.20%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$9.70 -0.01 (-0.10%)

As of 06/23/2025 04:10 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time